<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00294437</url>
  </required_header>
  <id_info>
    <org_study_id>CECOG/prostate 1.2.001</org_study_id>
    <nct_id>NCT00294437</nct_id>
  </id_info>
  <brief_title>ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases</brief_title>
  <official_title>Randomised Open-label Multicenter Prosp. Clinical Study to Show the Efficacy of IV ZOMETA® 4mg for Prevention of Bone Metastases in Hormone-naïve High Risk Patients With Locally Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central European Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central European Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if therapy with Zometa® (zoledronic acid) 4mg will be effective in preventing
      the occurrence of bone metastases in prostate cancer patients at high risk of developing
      them. In addition, pain and analgesic scores and overall safety are to be evaluated
      throughout the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, stratified open-label (Zometa + hormonal ablation versus
      hormonal ablation alone) multicenter clinical study evaluating the efficacy of Zometa 4mg
      given every 3 month as an adjunct to hormonal or surgical castration for prevention of bone
      metastases in locally advanced, high risk prostate cancer patients, who are hormone-naiv at
      time of randomization. the primary efficacy variable is the time to occurrence of first bone
      metastases.

      Zometa® (zoledronic acid) provided as 4mg lyophilised powder Supplementation 500mg Calcium
      +400-500IU Vitamin D p.o. qd

      Arm A:

      Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion
      every 3 months

      Arm B:

      no reference therapy
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    underfunding
  </why_stopped>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to occurrence of first bone metastasis, as assessed by bone scan and confirmed by additional radiological examination</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of i.v. Zometa® (zoledronic acid) 4 mg, with respect to the following efficacy parameters as well as safety and tolerability:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on pain and analgesic drug consumption, assessed by the composite pain score from BPI (Brief Pain Inventory) for pain and by analgesic score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first event of bone pain</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of Skeletal Related Events (SREs), defined as pathologic bone fractures, spinal cord compression, surgery to bone, radiation therapy to bone (including the use of radioisotopes)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in each arm having SRE</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum PSA</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall safety</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">376</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>zoledronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no reference therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zometa</intervention_name>
    <description>Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months</description>
    <arm_group_label>zoledronic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Age &gt; 18 years

          -  Histologically confirmed diagnosis of carcinoma of the prostate

          -  ECOG performance status of 0, 1, or 2

          -  No radiological evident bone metastasis (negative bone scan or verification of
             suspected foci as benign lesions by additional radiological examination)

          -  T3-4 AND highest pre-study PSA &gt;20 ng/ml AND Gleason score = 8 (or Gleason grade = 4)

          -  Patients with prior prostatectomy or prior local radiotherapy are eligible for this
             study

          -  Patients are destined to receive medical (LHRH analogue) or surgical (orchiectomy)
             castration and Zometa® treatment will start not later than 6 weeks after surgery

          -  Patients should be fully recovered from prior interventions where applicable

        Exclusion Criteria:

          -  Patients with a serum creatinine determination &gt;265 µmol/L (3.0 mg/dL)

          -  Patients that received prior medical (LHRH analogue) castration

          -  Current (or previous) evidence of metastatic disease to the bone

          -  History of any other neoplasm within the past five years except for nonmelanomatous
             skin cancer.

          -  Previous hormonal therapy with LHRH agonists or other forms of hormonal ablation

          -  WBC&lt;3.0x109, ANC &lt; 1500/mm3, Hgb&lt;8.0 g/dL, platelets &lt; 75 x 109/L

          -  Liver function tests &gt;2.5 ULN

          -  Prior treatment with Zometa® (zoledronic acid) or other bisphosphonates

          -  Treatment with calcitonin, mithramycin, or gallium nitrate within 2 weeks prior to the
             date of randomization (Visit 2)

          -  Use of other investigational drugs (drugs not marketed for any indication) within 30
             days prior to the date of randomization (Visit 2)

          -  Patients with evidence in the six months prior to randomization of severe
             cardiovascular disease (defined as uncontrolled congestive heart failure),
             hypertension refractory to treatment, or symptomatic coronary artery disease
             uncontrolled by treatment

          -  History of noncompliance to medical regimens and patients who are considered
             potentially unreliable or incapable of giving informed consent as judged by the
             investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bobak Djavan, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univ. Klinik für Urologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LKH Leoben, Abt. für Innere Medizin</name>
      <address>
        <city>Leoben</city>
        <state>Steiermark</state>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thermenkh Baden, Urologie</name>
      <address>
        <city>Baden bei Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Graz Univ. Klinik f Urologie</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Innsbruck, Dept f. Urologie</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH d Elisabethinen Linz, Dep of Urology</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH der Barmherzigen Schwestern, Dept Urologie</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Salzburg, Clinic f Radiotherapy a Radiooncology</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Oncology</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plovdiv Cancer Center</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBALO National Oncology Center</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBALO National Oncology Center</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sofia Cancer Center compl. Mladost ,</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MODOSZ Oncology Dispensary</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Modozs-Veliko</name>
      <address>
        <city>Tarnovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncological Hospital</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Hospital, Dep of Pathophysiology</name>
      <address>
        <city>Split</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GH, Dep Oncology and Reumatology</name>
      <address>
        <city>Varazdin</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FH, Urological Clinic</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Kromeriz, Dep of Urology</name>
      <address>
        <city>Kromeriz</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Motol, Dep of Urology</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre of Oncology</name>
      <address>
        <city>Usti Nad Labem</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mustamae Korpus</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of surgery</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. Of Urology , Jahn Ferenc Delpesti Hospital</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>karolyi sandor Hospital, Dept of Urology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweiss Univ of Medicine, Clinic of Urology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Pecs,Urologic Clinic</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. Of Urology and Surgery</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lithuanian Oncology Center</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Montenegro</name>
      <address>
        <city>Podgorica</city>
        <country>Montenegro</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Instytut</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Academy</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Rail Hospital,</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Academy</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.D.R. Clinic</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundeni Hospital, Dep of Urology</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John Emergency Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Cluj</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Clinical County Hospital , Clin Oncol. Dep</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hertzen Research Oncological Institute</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Radiological Research Center</name>
      <address>
        <city>Obninsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute Belgrade</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Oncology</name>
      <address>
        <city>Sremska Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FNsP - akad L. Derea Urology</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FNsP Dep of Urology</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN sP Dep of Urology</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Center</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gh, Dep of Urology</name>
      <address>
        <city>Maribor</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turret House</name>
      <address>
        <city>Claremont</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannesburg Hospital Dep of Urology</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Annes Hospital</name>
      <address>
        <city>Pietermaritzburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological Hospital</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Montenegro</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <link>
    <url>http://www.cecog.org</url>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2006</study_first_submitted>
  <study_first_submitted_qc>February 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2006</study_first_posted>
  <last_update_submitted>April 30, 2012</last_update_submitted>
  <last_update_submitted_qc>April 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2012</last_update_posted>
  <responsible_party>
    <organization>CECOG</organization>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Zometa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

